TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02253550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
Study: NCT04482166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic airway device
Description: supraglottic airway device
Study: NCT03393065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid management guided by BLS
Description: We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
Study: NCT03229525

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Related Expressive Writing
Description: Participants will write about the traumatic event over the course of six sessions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Expressive Writing
Description: Participants will write about a neutral event over the course of six sessions.
Study: NCT03650244

Intervention type: DEVICE
Intervention: REMEEX implantation
Description: Device implantation
Study: NCT02672514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Description: Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Description: Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
Study: NCT00002855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine Phosphate Sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Surgical castration
Study: NCT03747159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab Injection
Description: Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
Study: NCT00584376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Gradually titrated dose ranging from 75mg po bid to 225mg po bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
Study: NCT03129971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma
Description: Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
Study: NCT02130271

Intervention type: DRUG
Intervention: Radioactive dye
Description: The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).

Intervention type: DRUG
Intervention: Radioactive dye
Description: The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).

Intervention type: RADIATION
Intervention: PET/MRI
Description: All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.

Intervention type: RADIATION
Intervention: PET/MRI
Description: All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.

Intervention type: OTHER
Intervention: Blood draw
Description: Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.

Intervention type: OTHER
Intervention: Blood draw
Description: Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
Study: NCT05274100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via prefilled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via on-body delivery system (OBDS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via on-body delivery system (OBDS)
Study: NCT02926495

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eCoin System
Description: Median nerve neurostimulator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eCoin System
Description: Median nerve neurostimulator.
Study: NCT00938132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimasartan, warfarin
Description: Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
Study: NCT02134847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS intervention schedule
Study: NCT01032070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: oral
Study: NCT00609323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and tetracaine cream 7%/7%
Description: One treatment of up to 400 cm2 Cream applied for 60 minutes.
Study: NCT03916731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARgraft AV
Description: Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePTFE AV graft (control)
Description: Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
Study: NCT00609323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One treatment of up to 400 cm2 Cream applied for 60 minutes.
Study: NCT02979613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily
Study: NCT03240406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicultural Healthy Diet
Description: An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Diet plus Self-Care
Description: Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
Study: NCT02783456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Noise
Description: The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Noise
Description: The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silence
Description: The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silence
Description: The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
Study: NCT01734252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
Study: NCT03863704

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
Study: NCT04022239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT04108221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy or laparotomy withTransversusAbdominis Plane Block
Description: The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy or laparotomy withTransversusAbdominis Plane Block
Description: The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance.
Study: NCT04489875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: The intervention would be chewing gum. The patients in the intervention arm would be asked to chew gum for 15 minutes before meals thrice a day.
Study: NCT00524004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CsbD Bovine IgG
Description: Three times a day for seven days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three times a day for seven days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CS17 Bovin IgG
Description: Three times a day for seven days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CS17 Bovin IgG
Description: Three times a day for seven days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CS17 Bovin IgG
Description: Three times a day for seven days
Study: NCT04306887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101 capsule
Description: Escalating doses starting at 200 mg bid.
Study: NCT03157739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MigraineManager: Individualized Self-Management Tool
Description: Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
Study: NCT02604550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet 7.5/325
Description: Percocet 7.5/325 will taken as needed up to every four hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet 7.5/325
Description: Percocet 7.5/325 will taken as needed up to every four hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn 500 mg
Description: Naprosyn 500 mg will be taken twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn 500 mg
Description: Naprosyn 500 mg will be taken twice daily.
Study: NCT03035435

Intervention type: OTHER
Intervention: fast-track rehabilitation

Intervention type: OTHER
Intervention: standard care rehabilitation
Study: NCT02568618

Intervention type: GENETIC
Group type: OTHER
Intervention: Pain Medication DNA Insight (TM) test
Description: The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.

Intervention type: GENETIC
Group type: OTHER
Intervention: Pain Medication DNA Insight (TM) test
Description: The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
Study: NCT02956057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycols

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycols

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrium picosulfate / Magnesium citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrium picosulfate / Magnesium citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol / Ascorbic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol / Ascorbic acid
Study: NCT03229629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change communication
Description: Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change communication
Description: Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change communication
Description: Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change communication
Description: Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Voucher (Monetary)
Description: Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Voucher (Monetary)
Description: Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Voucher (Monetary)
Description: Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month
Study: NCT04518969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist.
Study: NCT04205344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mg
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 10 mg
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
Study: NCT02979613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF
Description: 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: Tablet administered orally once daily
Study: NCT00057044

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: education and reminder
Study: NCT03619551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell processing for TCRαβ+/CD19+ depletion
Description: T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell processing for TCRαβ+/CD19+ depletion
Description: T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
Study: NCT01079754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal morphine 0.05 mg
Description: Patient received spinal morphine 0.05 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal morphine 0.1 mg
Description: Patient received spinal morphine 0.1 mg
Study: NCT00699231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: IM injection